# E2R Stock-Web Historical Calibration / Sector-Archetype Residual Research Round

## 0. Research Metadata

```text
research_session = post_calibrated_sector_archetype_residual_research
mode = historical_trigger_level_calibration_after_stock_web_ohlc_breakthrough_v12
scheduled_round = R7
scheduled_loop = 92
round_schedule_status = valid
round_sector_consistency = pass
large_sector_id = L7_BIO_HEALTHCARE_MEDICAL
canonical_archetype_id = C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION
fine_archetype_id = BIO_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_BRIDGE_VS_PHARMA_CHANNEL_FALSE_STAGE2_AND_GENE_THERAPY_EVENT_CAP
loop_objective = coverage_gap_fill | counterexample_mining | stage2_actionable_bonus_stress_test | 4B_non_price_requirement_stress_test | high_MAE_guardrail | canonical_archetype_compression
output_file = e2r_stock_web_v12_residual_round_R7_loop_92_L7_BIO_HEALTHCARE_MEDICAL_C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION_research.md
```

This file is the corrected final output for this execution. The scheduler state after R6 loop 92 is R7 / loop 92. It fills C23 bio regulatory approval / commercialization behavior after the prior R7 loop 91 used C25, loop 90 used C24, and loop 89 used C23 with different symbols.

## 1. Current Calibrated Profile Assumption

```text
current_default_profile_proxy = e2r_2_1_stock_web_calibrated
previous_baseline_reference = e2r_2_0_baseline
production_scoring_changed = false
shadow_weight_only = true
```

Existing axes tested:

```text
stage2_required_bridge = existing_axis_strengthened
local_4b_watch_guard = existing_axis_strengthened
high_MAE_guardrail = existing_axis_strengthened
full_4b_requires_non_price_evidence = existing_axis_kept
price_only_blowoff_blocks_positive_stage = existing_axis_kept
hard_4c_thesis_break_routes_to_4c = existing_axis_kept
```

## 2. Round / Large Sector / Canonical Archetype Scope

```text
scheduled_round = R7
scheduled_loop = 92
large_sector_id = L7_BIO_HEALTHCARE_MEDICAL
canonical_archetype_id = C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION
round_sector_consistency = pass
computed_next_round = R8
computed_next_loop = 92
```

R7 permits L7 bio / healthcare / medical research. This loop avoids the recent R7 C25/C24 symbol sets and returns to C23 with a fresh platform-license / regulatory-commercialization split.

## 3. Previous Coverage / Duplicate Avoidance Check

No-Repeat hard key used:

```text
canonical_archetype_id + symbol + trigger_type + entry_date
```

No-Repeat snapshot context:

```text
C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION = 26 rows / 14 symbols / good-bad Stage2 8-5 / 4B-4C 0-2
top covered symbols include UNKNOWN_SYMBOL(6), 028300(4), 000100(2), 039200(2), 195940(2), 003850(1)
previous R7 loop-89 C23 symbols avoided: 000250, 086900, 068760
previous R7 loop-90 C24 symbols avoided: 397030, 365270, 067630
previous R7 loop-91 C25 symbols avoided: 206640, 043150, 246710
previous R6 loop-92 C21 symbols avoided: 175330, 003470, 016610
```

Selected rows avoid hard duplicate keys:

```text
196170 / Stage2-Actionable / 2024-02-23
003850 / Stage2-Actionable / 2024-03-20
950160 / Stage4B / 2024-07-15
```

`003850` is a reduced-weight soft expansion because it appears lightly in existing C23 coverage. `196170` and `950160` are new symbols for this C23 fine split.

## 4. Stock-Web OHLC Input / Price Source Validation

| field | value |
|---|---|
| source | Songdaiki/stock-web |
| upstream_source | FinanceData/marcap |
| manifest | atlas/manifest.json |
| stock_web_manifest_max_date | 2026-02-20 |
| price_basis | tradable_raw |
| price_adjustment_status | raw_unadjusted_marcap |
| calibration_shard_root | atlas/ohlcv_tradable_by_symbol_year |

| symbol | profile path | CA window status |
|---|---|---|
| 196170 | atlas/symbol_profiles/196/196170.json | selected 2024 window clean after old 2017/2020/2021 CA candidates |
| 003850 | atlas/symbol_profiles/003/003850.json | selected 2024 window clean after historical name/CA periods |
| 950160 | atlas/symbol_profiles/950/950160.json | selected 2024 window clean after 2022-10-25 CA and post-suspension tradable history |

## 5. Historical Eligibility Gate

| case_id | symbol | entry_date | entry in shard | forward 180D | OHLC valid | CA clean | calibration_usable |
|---|---|---:|---|---:|---|---|---|
| R7L92_C23_ALTEOGEN_2024_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_POSITIVE | 196170 | 2024-02-23 | yes | 180 | yes | yes | true |
| R7L92_C23_BORYUNG_2024_PHARMA_COMMERCIALIZATION_CHANNEL_FALSE_STAGE2 | 003850 | 2024-03-20 | yes | 180 | yes | yes | true |
| R7L92_C23_KOLONTISSUEGENE_2024_GENE_THERAPY_REGULATORY_EVENT_CAP_4B | 950160 | 2024-07-15 | yes | 180 | yes | yes | true |

## 6. Canonical Archetype Compression Map

| canonical | fine/deep split | meaning |
|---|---|---|
| C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION | BIO_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_BRIDGE | Positive Stage2 requires partner quality, license economics, regulatory path, milestone visibility, commercialization and revision bridge. |
| C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION | PHARMA_CHANNEL_FALSE_STAGE2 | Pharma commercialization/channel watch without approval/reimbursement bridge can become false Stage2. |
| C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION | GENE_THERAPY_EVENT_CAP_4B | Regulatory/gene-therapy event premium should route to 4B when approval/commercial bridge is missing. |

## 7. Case Selection Summary

| case_id | symbol | company | role | selected reason |
|---|---|---|---|---|
| R7L92_C23_ALTEOGEN_2024_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_POSITIVE | 196170 | 알테오젠 | positive | Platform-license / regulatory-commercialization bridge produced very high MFE with controlled early MAE. |
| R7L92_C23_BORYUNG_2024_PHARMA_COMMERCIALIZATION_CHANNEL_FALSE_STAGE2 | 003850 | 보령 | counterexample | Commercialization/channel watch had small MFE and persistent 90D/180D MAE. |
| R7L92_C23_KOLONTISSUEGENE_2024_GENE_THERAPY_REGULATORY_EVENT_CAP_4B | 950160 | 코오롱티슈진 | counterexample / 4B | Gene-therapy regulatory event premium capped around the July spike and then de-rated. |

## 8. Positive vs Counterexample Balance

```text
positive_case_count = 1
counterexample_count = 2
4B_case_count = 1
4C_case_count = 0
calibration_usable_case_count = 3
calibration_usable_trigger_count = 3
```

## 9. Evidence Source Map

| case | evidence status | evidence_url_pending | source_proxy_only | usage |
|---|---|---|---|---|
| Alteogen platform-license commercialization bridge | historical public/report proxy | true | true | shadow-only positive |
| Boryung pharma channel false Stage2 | historical public/news proxy | true | true | false-Stage2 guardrail |
| Kolon TissueGene regulatory event cap | historical public/news proxy | true | true | 4B overlay counterexample |

## 10. Price Data Source Map

| symbol | shard | profile |
|---|---|---|
| 196170 | atlas/ohlcv_tradable_by_symbol_year/196/196170/2024.csv | atlas/symbol_profiles/196/196170.json |
| 003850 | atlas/ohlcv_tradable_by_symbol_year/003/003850/2024.csv | atlas/symbol_profiles/003/003850.json |
| 950160 | atlas/ohlcv_tradable_by_symbol_year/950/950160/2024.csv | atlas/symbol_profiles/950/950160.json |

## 11. Case-by-Case Trigger Grid

| trigger_id | symbol | trigger_type | entry_date | entry_price | role | verdict |
|---|---|---|---:|---:|---|---|
| R7L92_C23_ALTEOGEN_2024_STAGE2_ACTIONABLE_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION | 196170 | Stage2-Actionable | 2024-02-23 | 131200 | positive | platform-license/regulatory-commercialization bridge worked |
| R7L92_C23_BORYUNG_2024_STAGE2_FALSE_POSITIVE_PHARMA_COMMERCIALIZATION_CHANNEL | 003850 | Stage2-Actionable | 2024-03-20 | 13140 | counterexample | pharma commercialization/channel false Stage2 |
| R7L92_C23_KOLONTISSUEGENE_2024_STAGE4B_GENE_THERAPY_REGULATORY_EVENT_CAP | 950160 | Stage4B | 2024-07-15 | 20300 | counterexample/4B | gene-therapy regulatory event cap |

## 12. Trigger-Level OHLC Backtest Tables

| trigger_id | entry | MFE30 | MAE30 | MFE90 | MAE90 | MFE180 | MAE180 | peak_date | peak_price | drawdown_after_peak |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| R7L92_C23_ALTEOGEN_2024_STAGE2_ACTIONABLE_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION | 131200 | 71.88 | -9.30 | 124.09 | -9.30 | 247.18 | -9.30 | 2024-11-11 | 455500 | -39.85 |
| R7L92_C23_BORYUNG_2024_STAGE2_FALSE_POSITIVE_PHARMA_COMMERCIALIZATION_CHANNEL | 13140 | 4.64 | -17.66 | 4.64 | -28.31 | 4.64 | -28.31 | 2024-03-20 | 13750 | -31.42 |
| R7L92_C23_KOLONTISSUEGENE_2024_STAGE4B_GENE_THERAPY_REGULATORY_EVENT_CAP | 20300 | 7.39 | -25.67 | 7.39 | -35.02 | 7.39 | -35.02 | 2024-07-15 | 21800 | -39.50 |

## 13. Current Calibrated Profile Stress Test

| axis | outcome |
|---|---|
| stage2_required_bridge | strengthen: C23 Stage2 needs partner/license/regulatory/commercialization/reimbursement/revision bridge |
| local_4b_watch_guard | strengthen: regulatory/gene-therapy event premiums should route to 4B watch when bridge is missing |
| high_MAE_guardrail | strengthen: high-MAE bio event rows cannot promote without durable commercial bridge |
| full_4b_requires_non_price_evidence | keep |
| price_only_blowoff_blocks_positive_stage | keep |
| hard_4c_thesis_break_routes_to_4c | keep; no hard 4C promoted |

## 14. Stage2 / Yellow / Green Comparison

No confirmed Stage3-Green row is introduced. The useful split is approval/commercialization bridge quality:

| symbol | stage quality | explanation |
|---|---|---|
| 196170 | good_stage2_with_later_watch | Platform-license/regulatory-commercialization bridge produced very high MFE. |
| 003850 | bad_stage2 | Commercialization/channel watch lacked approval/reimbursement/revision bridge and had persistent MAE. |
| 950160 | good_4B | Gene-therapy regulatory event premium capped around the July spike. |

```text
green_lateness_ratio = not_applicable
reason = no confirmed Stage3-Green trigger
```

## 15. 4B Local vs Full-window Timing Audit

| trigger | local proximity | full-window proximity | timing verdict |
|---|---:|---:|---|
| 003850 pharma channel false Stage2 | 0.96 | 0.96 | false Stage2 due missing approval/reimbursement revision bridge |
| 950160 gene-therapy event cap | 0.93 | 0.93 | good full-window 4B timing |
| 196170 platform-license bridge | n/a | n/a | positive Stage2, but later bio-platform valuation watch required |

## 16. 4C Protection Audit

```text
4C_case_count = 0
four_c_protection_label = thesis_break_watch_only for 003850 / 950160
```

No hard 4C candidate is proposed. R7 loop 92 is about Stage2 bridge quality and 4B event-cap timing.

## 17. Sector-Specific Rule Candidate

```text
sector_specific_rule_candidate = true
rule_scope = sector_specific
rule = In L7 bio regulatory approval/commercialization cases, Stage2 requires verified partner quality, license economics, regulatory path, approval/commercial milestone, reimbursement, channel execution, margin, or revision bridge. Bio, pharma, gene-therapy, regulatory, approval, commercialization, or event label alone remains watch/4B.
proposal_status = shadow_only
```

## 18. Canonical-Archetype Rule Candidate

```text
canonical_archetype_rule_candidate = true
canonical_archetype_id = C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION
rule = C23 should split true partner-license/regulatory commercialization positives from pharma channel false Stage2 and regulatory/gene-therapy event caps. Event-cap rows are 4B overlay/risk calibration, not Stage3-Green promotion evidence.
proposal_status = shadow_only_not_production
```

## 19. Before / After Backtest Comparison

| profile | hypothesis | eligible triggers | avg_MFE90 | avg_MAE90 | false_positive_rate | verdict |
|---|---|---:|---:|---:|---:|---|
| P0 e2r_2_1_stock_web_calibrated_proxy | current profile | 3 | 45.37 | -24.21 | 0.67 | mixed; C23 bridge split needed |
| P0b e2r_2_0_baseline_reference | older baseline | 3 | 45.37 | -24.21 | 0.67 | weaker bridge/event-cap guard |
| P1 sector_specific_candidate_profile | L7 partner/license/commercial bridge required | 2 | 64.37 | -18.81 | 0.50 | better |
| P2 canonical_archetype_candidate_profile | C23 bridge vs event-cap split | 2 | 64.37 | -18.81 | 0.50 | best explanatory fit |
| P3 counterexample_guard_profile | reject bridge-missing bio events as positive | 1 | 124.09 | -9.30 | 0.00 | safest but source-proxy blockers remain |

## 20. Score-Return Alignment Matrix

| trigger | score before | stage before | score after | stage after | MFE90 | MAE90 | alignment |
|---|---:|---|---:|---|---:|---:|---|
| 196170 platform-license bridge | 66 | Stage2-Watch | 78 | Stage2-Actionable | 124.09 | -9.30 | platform_license_regulatory_commercialization_positive |
| 003850 pharma channel false | 66 | Stage2-Actionable | 53 | Stage1/Watch | 4.64 | -28.31 | pharma_commercialization_channel_false_stage2 |
| 950160 gene therapy event cap | 70 | Stage3-Yellow-like | 54 | Stage4B-watch | 7.39 | -35.02 | gene_therapy_regulatory_event_cap_4B_guard |

## 21. Coverage Matrix

```jsonl
{"row_type": "coverage_matrix", "large_sector_id": "L7_BIO_HEALTHCARE_MEDICAL", "canonical_archetype_id": "C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION", "fine_archetype_id": "BIO_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_BRIDGE_VS_PHARMA_CHANNEL_FALSE_STAGE2_AND_GENE_THERAPY_EVENT_CAP", "positive_case_count": 1, "counterexample_count": 2, "4B_case_count": 1, "4C_case_count": 0, "new_independent_case_count": 3, "reused_case_count": 0, "calibration_usable_trigger_count": 3, "representative_trigger_count": 2, "current_profile_error_count": 2, "sector_rule_candidate": true, "canonical_rule_candidate": true, "coverage_gap_after_this_loop": "Adds C23 platform-license regulatory commercialization positive, pharma-channel false Stage2, and gene-therapy regulatory event-cap 4B split using non-top-covered or reduced-weight lightly covered symbols."}
```

## 22. Residual Contribution Summary

```text
new_independent_case_count: 3
reused_case_count: 0
reused_case_ids: []
new_symbol_count: 2
new_canonical_archetype_count: 0
new_fine_archetype_count: 1
new_trigger_family_count: 3
tested_existing_calibrated_axes: stage2_required_bridge, local_4b_watch_guard, high_MAE_guardrail, full_4b_requires_non_price_evidence, price_only_blowoff_blocks_positive_stage
residual_error_types_found: platform_license_regulatory_commercialization_positive, pharma_commercialization_channel_false_stage2, gene_therapy_regulatory_event_cap_4B
new_axis_proposed: null
existing_axis_strengthened: stage2_required_bridge, local_4b_watch_guard, high_MAE_guardrail
existing_axis_weakened: null
existing_axis_kept: full_4b_requires_non_price_evidence, price_only_blowoff_blocks_positive_stage, hard_4c_thesis_break_routes_to_4c
sector_specific_rule_candidate: true
canonical_archetype_rule_candidate: true
no_new_signal_reason: null
loop_contribution_label: canonical_archetype_rule_candidate
do_not_propose_new_weight_delta: true
```

## 23. Validation Scope / Non-Validation Scope

Validation scope:

```text
- Stock-web tradable raw OHLC path
- entry_date / entry_price
- MFE/MAE 30D/90D/180D
- corporate-action window cleanliness
- C23 bio regulatory approval/commercialization bridge vs false Stage2 / event-cap split
```

Non-validation scope:

```text
- Exact as-of evidence URLs remain pending for all selected cases.
- No production scoring update.
- No live candidate scan.
- No investment recommendation.
```

## 24. Shadow Weight Calibration

```csv
row_type,axis,scope,large_sector_id,canonical_archetype_id,baseline_value,tested_value,delta,reason,backtest_effect,trigger_ids,calibration_usable_count,new_independent_case_count,counterexample_count,confidence,proposal_type,notes
shadow_weight,stage2_required_bridge,canonical_archetype,L7_BIO_HEALTHCARE_MEDICAL,C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION,configured,C23_requires_partner_license_regulatory_commercialization_reimbursement_revision_bridge,0,"C23 Stage2 should require high-quality partner, license economics, regulatory path, approval/commercialization milestone, reimbursement/channel execution, margin, or revision bridge, not bio/regulatory label alone","Alteogen positive worked; Boryung and Kolon TissueGene event/watch rows failed positive-stage promotion","R7L92_C23_ALTEOGEN_2024_STAGE2_ACTIONABLE_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION|R7L92_C23_BORYUNG_2024_STAGE2_FALSE_POSITIVE_PHARMA_COMMERCIALIZATION_CHANNEL|R7L92_C23_KOLONTISSUEGENE_2024_STAGE4B_GENE_THERAPY_REGULATORY_EVENT_CAP",3,3,2,low,canonical_shadow_only,"do_not_propose_new_weight_delta=true because source-proxy/evidence-url-pending rows remain"
shadow_weight,local_4b_watch_guard,canonical_archetype,L7_BIO_HEALTHCARE_MEDICAL,C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION,configured,cap_bridge_missing_regulatory_and_gene_therapy_event_premiums_as_4B_watch,0,"Regulatory approval and gene-therapy event premiums can peak before partner economics and commercialization bridge is proven","Boryung had weak forward MFE and Kolon TissueGene showed 4B event-cap behavior after July spike","R7L92_C23_BORYUNG_2024_STAGE2_FALSE_POSITIVE_PHARMA_COMMERCIALIZATION_CHANNEL|R7L92_C23_KOLONTISSUEGENE_2024_STAGE4B_GENE_THERAPY_REGULATORY_EVENT_CAP",2,2,2,medium,guardrail_shadow_only,"4B overlay only; not production"
shadow_weight,high_MAE_guardrail,canonical_archetype,L7_BIO_HEALTHCARE_MEDICAL,C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION,configured,block_positive_stage_when_bio_event_has_high_MAE_without_commercial_bridge,0,"High MAE after a bridge-missing regulatory/commercialization entry should block Stage2/Stage3 promotion unless partner, approval, reimbursement, and revision evidence survives","Boryung MAE90=-28.31 and Kolon TissueGene MAE90=-35.02","R7L92_C23_BORYUNG_2024_STAGE2_FALSE_POSITIVE_PHARMA_COMMERCIALIZATION_CHANNEL|R7L92_C23_KOLONTISSUEGENE_2024_STAGE4B_GENE_THERAPY_REGULATORY_EVENT_CAP",2,2,2,medium,guardrail_shadow_only,"canonical shadow profile only"
```

## 25. Machine-Readable Rows

### 25.1 price_source_validation

```jsonl
{"row_type": "price_source_validation", "source": "Songdaiki/stock-web", "source_url": "https://github.com/Songdaiki/stock-web", "manifest_path": "atlas/manifest.json", "schema_path": "atlas/schema.json", "universe_path": "atlas/universe/all_symbols.csv", "manifest_max_date": "2026-02-20", "price_basis": "tradable_raw", "price_adjustment_status": "raw_unadjusted_marcap", "calibration_shard_root": "atlas/ohlcv_tradable_by_symbol_year", "raw_shard_root": "atlas/ohlcv_raw_by_symbol_year", "validation_status": "usable_for_historical_calibration", "source_name": "FinanceData/marcap", "tradable_row_count": 14354401, "raw_row_count": 15214118, "symbol_count": 5414, "active_like_symbol_count": 2868, "inactive_or_delisted_like_symbol_count": 2546}
```

### 25.2 case rows

```jsonl
{"row_type": "case", "case_id": "R7L92_C23_ALTEOGEN_2024_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_POSITIVE", "symbol": "196170", "company_name": "알테오젠", "round": "R7", "loop": "92", "large_sector_id": "L7_BIO_HEALTHCARE_MEDICAL", "canonical_archetype_id": "C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION", "fine_archetype_id": "BIO_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_BRIDGE_VS_PHARMA_CHANNEL_FALSE_STAGE2_AND_GENE_THERAPY_EVENT_CAP", "case_type": "structural_success_with_later_valuation_watch", "positive_or_counterexample": "positive", "best_trigger": "R7L92_C23_ALTEOGEN_2024_STAGE2_ACTIONABLE_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION", "calibration_usable": true, "is_new_independent_case": true, "reuse_reason": null, "independent_evidence_weight": 1.0, "score_price_alignment": "Bio-platform license / regulatory commercialization bridge produced very high 30D/90D/180D MFE with controlled early MAE. C23 works when approval/commercialization narrative maps into partner quality, license economics, regulatory path, milestone visibility, and margin/revision bridge.", "current_profile_verdict": "current_profile_kept_but_C23_positive_requires_partner_license_regulatory_commercialization_bridge_not_bio_label_only", "price_source": "Songdaiki/stock-web", "notes": "Selected 2024 window clean after old 2017/2020/2021 CA candidates. Source-proxy only, so no production weight delta."}
{"row_type": "case", "case_id": "R7L92_C23_BORYUNG_2024_PHARMA_COMMERCIALIZATION_CHANNEL_FALSE_STAGE2", "symbol": "003850", "company_name": "보령", "round": "R7", "loop": "92", "large_sector_id": "L7_BIO_HEALTHCARE_MEDICAL", "canonical_archetype_id": "C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION", "fine_archetype_id": "BIO_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_BRIDGE_VS_PHARMA_CHANNEL_FALSE_STAGE2_AND_GENE_THERAPY_EVENT_CAP", "case_type": "failed_rerating_commercialization_channel_bridge_missing", "positive_or_counterexample": "counterexample", "best_trigger": "R7L92_C23_BORYUNG_2024_STAGE2_FALSE_POSITIVE_PHARMA_COMMERCIALIZATION_CHANNEL", "calibration_usable": true, "is_new_independent_case": true, "reuse_reason": "Soft expansion: 003850 appears lightly in C23 coverage, but this row uses a new 2024 entry date and pharma-commercialization/channel false-Stage2 family.", "independent_evidence_weight": 0.75, "score_price_alignment": "Pharma commercialization / prescription-channel recovery watch had only small forward MFE and then persistent 90D/180D MAE. C23 Stage2 should not be awarded without approved-label expansion, reimbursement, channel sell-through, partner/commercial execution, and revision bridge.", "current_profile_verdict": "current_profile_false_positive_if_pharma_commercialization_channel_counts_without_approval_reimbursement_revision_bridge", "price_source": "Songdaiki/stock-web", "notes": "Selected 2024 window clean after historical name/corporate-action periods. Reduced weight because 003850 already appears once in C23 coverage."}
{"row_type": "case", "case_id": "R7L92_C23_KOLONTISSUEGENE_2024_GENE_THERAPY_REGULATORY_EVENT_CAP_4B", "symbol": "950160", "company_name": "코오롱티슈진", "round": "R7", "loop": "92", "large_sector_id": "L7_BIO_HEALTHCARE_MEDICAL", "canonical_archetype_id": "C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION", "fine_archetype_id": "BIO_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_BRIDGE_VS_PHARMA_CHANNEL_FALSE_STAGE2_AND_GENE_THERAPY_EVENT_CAP", "case_type": "event_cap_4b_counterexample", "positive_or_counterexample": "counterexample", "best_trigger": "R7L92_C23_KOLONTISSUEGENE_2024_STAGE4B_GENE_THERAPY_REGULATORY_EVENT_CAP", "calibration_usable": true, "is_new_independent_case": true, "reuse_reason": null, "independent_evidence_weight": 1.0, "score_price_alignment": "Gene-therapy / regulatory event premium capped around the July spike and then suffered severe MAE. C23 should route bridge-missing regulatory event premiums to 4B unless approval milestone, label/commercial path, reimbursement, partner economics, and execution bridge remain visible.", "current_profile_verdict": "current_profile_4B_too_late_if_gene_therapy_regulatory_event_premium_not_capped", "price_source": "Songdaiki/stock-web", "notes": "Selected 2024 window clean after 2022-10-25 CA candidate and post-suspension tradable history. Source-proxy only."}
```

### 25.3 trigger rows

```jsonl
{"row_type": "trigger", "trigger_id": "R7L92_C23_ALTEOGEN_2024_STAGE2_ACTIONABLE_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION", "case_id": "R7L92_C23_ALTEOGEN_2024_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_POSITIVE", "symbol": "196170", "company_name": "알테오젠", "round": "R7", "loop": "92", "large_sector_id": "L7_BIO_HEALTHCARE_MEDICAL", "canonical_archetype_id": "C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION", "fine_archetype_id": "BIO_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_BRIDGE_VS_PHARMA_CHANNEL_FALSE_STAGE2_AND_GENE_THERAPY_EVENT_CAP", "sector": "bio_platform_license_regulatory_commercialization", "primary_archetype": "partner_license_regulatory_path_milestone_commercial_bridge", "loop_objective": "coverage_gap_fill | counterexample_mining | stage2_actionable_bonus_stress_test | 4B_non_price_requirement_stress_test | high_MAE_guardrail | canonical_archetype_compression", "trigger_type": "Stage2-Actionable", "trigger_date": "2024-02-23", "entry_date": "2024-02-23", "entry_price": 131200.0, "evidence_available_at_that_date": "bio-platform licensing, high-quality partner, regulatory/commercialization path, milestone economics and revision bridge proxy; exact as-of source URL pending", "evidence_source": "source_proxy_historical_public_report_proxy", "stage2_evidence_fields": ["partner_quality_proxy", "license_economics_proxy", "regulatory_path_proxy", "milestone_visibility_proxy", "commercialization_revision_bridge_proxy"], "stage3_evidence_fields": ["very_high_MFE30", "very_high_MFE90", "very_high_MFE180", "controlled_initial_MAE"], "stage4b_evidence_fields": ["later_bio_platform_valuation_watch", "positioning_overheat_watch"], "stage4c_evidence_fields": [], "price_data_source": "Songdaiki/stock-web", "price_data_repo": "https://github.com/Songdaiki/stock-web", "price_shard_path": "atlas/ohlcv_tradable_by_symbol_year/196/196170/2024.csv", "profile_path": "atlas/symbol_profiles/196/196170.json", "price_basis": "tradable_raw", "price_adjustment_status": "raw_unadjusted_marcap", "stock_web_manifest_max_date": "2026-02-20", "MFE_30D_pct": 71.88, "MFE_90D_pct": 124.09, "MFE_180D_pct": 247.18, "MFE_1Y_pct": "not_calculated", "MFE_2Y_pct": "not_calculated", "MAE_30D_pct": -9.3, "MAE_90D_pct": -9.3, "MAE_180D_pct": -9.3, "MAE_1Y_pct": "not_calculated", "below_entry_price_flag_30D": true, "below_entry_price_flag_90D": true, "peak_date": "2024-11-11", "peak_price": 455500.0, "drawdown_after_peak_pct": -39.85, "green_lateness_ratio": "not_applicable", "four_b_local_peak_proximity": null, "four_b_full_window_peak_proximity": null, "four_b_timing_verdict": "positive_stage2_but_later_bio_platform_valuation_watch_needed", "four_b_evidence_type": ["valuation_repricing", "positioning_overheat", "platform_license_premium"], "four_c_protection_label": "not_applicable", "trigger_outcome_label": "good_stage2_platform_license_regulatory_commercialization_bridge_success", "current_profile_verdict": "current_profile_kept_but_source_proxy_blocks_positive_delta", "calibration_usable": true, "forward_window_trading_days": 180, "calibration_block_reasons": [], "corporate_action_window_status": "clean_180D_window_after_old_2021_CA", "same_entry_group_id": "R7L92_C23_196170_2024-02-23_131200", "dedupe_for_aggregate": true, "aggregate_group_role": "representative", "is_new_independent_case": true, "reuse_reason": null, "independent_evidence_weight": 1.0, "do_not_count_as_new_case": false, "evidence_url_pending": true, "source_proxy_only": true}
{"row_type": "trigger", "trigger_id": "R7L92_C23_BORYUNG_2024_STAGE2_FALSE_POSITIVE_PHARMA_COMMERCIALIZATION_CHANNEL", "case_id": "R7L92_C23_BORYUNG_2024_PHARMA_COMMERCIALIZATION_CHANNEL_FALSE_STAGE2", "symbol": "003850", "company_name": "보령", "round": "R7", "loop": "92", "large_sector_id": "L7_BIO_HEALTHCARE_MEDICAL", "canonical_archetype_id": "C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION", "fine_archetype_id": "BIO_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_BRIDGE_VS_PHARMA_CHANNEL_FALSE_STAGE2_AND_GENE_THERAPY_EVENT_CAP", "sector": "pharma_commercialization_channel_recovery_watch", "primary_archetype": "commercialization_channel_watch_without_approval_reimbursement_revision_bridge", "loop_objective": "coverage_gap_fill | counterexample_mining | stage2_actionable_bonus_stress_test | 4B_non_price_requirement_stress_test | high_MAE_guardrail | canonical_archetype_compression", "trigger_type": "Stage2-Actionable", "trigger_date": "2024-03-20", "entry_date": "2024-03-20", "entry_price": 13140.0, "evidence_available_at_that_date": "pharma commercialization / channel recovery watch and approval/reimbursement expectation proxy; exact as-of source URL pending", "evidence_source": "source_proxy_historical_public_news_proxy", "stage2_evidence_fields": ["commercialization_channel_watch", "approval_reimbursement_expectation", "relative_strength_spike"], "stage3_evidence_fields": [], "stage4b_evidence_fields": ["limited_MFE90", "commercial_execution_revision_bridge_missing", "post_spike_drawdown"], "stage4c_evidence_fields": ["thesis_break_watch_only"], "price_data_source": "Songdaiki/stock-web", "price_data_repo": "https://github.com/Songdaiki/stock-web", "price_shard_path": "atlas/ohlcv_tradable_by_symbol_year/003/003850/2024.csv", "profile_path": "atlas/symbol_profiles/003/003850.json", "price_basis": "tradable_raw", "price_adjustment_status": "raw_unadjusted_marcap", "stock_web_manifest_max_date": "2026-02-20", "MFE_30D_pct": 4.64, "MFE_90D_pct": 4.64, "MFE_180D_pct": 4.64, "MFE_1Y_pct": "not_calculated", "MFE_2Y_pct": "not_calculated", "MAE_30D_pct": -17.66, "MAE_90D_pct": -28.31, "MAE_180D_pct": -28.31, "MAE_1Y_pct": "not_calculated", "below_entry_price_flag_30D": true, "below_entry_price_flag_90D": true, "peak_date": "2024-03-20", "peak_price": 13750.0, "drawdown_after_peak_pct": -31.42, "green_lateness_ratio": "not_applicable", "four_b_local_peak_proximity": 0.96, "four_b_full_window_peak_proximity": 0.96, "four_b_timing_verdict": "pharma_commercialization_channel_watch_was_false_stage2_due_missing_approval_reimbursement_revision_bridge", "four_b_evidence_type": ["pharma_channel_premium", "positioning_overheat", "bridge_missing"], "four_c_protection_label": "thesis_break_watch_only", "trigger_outcome_label": "bad_stage2_pharma_commercialization_channel_without_approval_reimbursement_bridge", "current_profile_verdict": "current_profile_false_positive_if_pharma_commercialization_channel_counts_without_approval_reimbursement_revision_bridge", "calibration_usable": true, "forward_window_trading_days": 180, "calibration_block_reasons": [], "corporate_action_window_status": "clean_180D_window_after_historical_name_CA_period", "same_entry_group_id": "R7L92_C23_003850_2024-03-20_13140", "dedupe_for_aggregate": true, "aggregate_group_role": "representative_soft_expansion", "is_new_independent_case": true, "reuse_reason": "soft_expansion_same_C23_symbol_new_entry_date_and_failure_family", "independent_evidence_weight": 0.75, "do_not_count_as_new_case": false, "evidence_url_pending": true, "source_proxy_only": true}
{"row_type": "trigger", "trigger_id": "R7L92_C23_KOLONTISSUEGENE_2024_STAGE4B_GENE_THERAPY_REGULATORY_EVENT_CAP", "case_id": "R7L92_C23_KOLONTISSUEGENE_2024_GENE_THERAPY_REGULATORY_EVENT_CAP_4B", "symbol": "950160", "company_name": "코오롱티슈진", "round": "R7", "loop": "92", "large_sector_id": "L7_BIO_HEALTHCARE_MEDICAL", "canonical_archetype_id": "C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION", "fine_archetype_id": "BIO_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_BRIDGE_VS_PHARMA_CHANNEL_FALSE_STAGE2_AND_GENE_THERAPY_EVENT_CAP", "sector": "gene_therapy_regulatory_event_premium", "primary_archetype": "gene_therapy_regulatory_event_cap_4B", "loop_objective": "coverage_gap_fill | counterexample_mining | stage2_actionable_bonus_stress_test | 4B_non_price_requirement_stress_test | high_MAE_guardrail | canonical_archetype_compression", "trigger_type": "Stage4B", "trigger_date": "2024-07-15", "entry_date": "2024-07-15", "entry_price": 20300.0, "evidence_available_at_that_date": "gene therapy / regulatory event premium after July spike; exact as-of source URL pending", "evidence_source": "source_proxy_historical_public_news_proxy", "stage2_evidence_fields": ["gene_therapy_regulatory_event", "approval_milestone_watch", "relative_strength_spike"], "stage3_evidence_fields": [], "stage4b_evidence_fields": ["event_premium_cap", "deep_MAE90", "approval_commercialization_bridge_recheck"], "stage4c_evidence_fields": ["thesis_break_watch_only"], "price_data_source": "Songdaiki/stock-web", "price_data_repo": "https://github.com/Songdaiki/stock-web", "price_shard_path": "atlas/ohlcv_tradable_by_symbol_year/950/950160/2024.csv", "profile_path": "atlas/symbol_profiles/950/950160.json", "price_basis": "tradable_raw", "price_adjustment_status": "raw_unadjusted_marcap", "stock_web_manifest_max_date": "2026-02-20", "MFE_30D_pct": 7.39, "MFE_90D_pct": 7.39, "MFE_180D_pct": 7.39, "MFE_1Y_pct": "not_calculated", "MFE_2Y_pct": "not_calculated", "MAE_30D_pct": -25.67, "MAE_90D_pct": -35.02, "MAE_180D_pct": -35.02, "MAE_1Y_pct": "not_calculated", "below_entry_price_flag_30D": true, "below_entry_price_flag_90D": true, "peak_date": "2024-07-15", "peak_price": 21800.0, "drawdown_after_peak_pct": -39.5, "green_lateness_ratio": "not_applicable", "four_b_local_peak_proximity": 0.93, "four_b_full_window_peak_proximity": 0.93, "four_b_timing_verdict": "good_full_window_4B_timing_gene_therapy_regulatory_event_cap", "four_b_evidence_type": ["regulatory_event_premium", "positioning_overheat", "price_only"], "four_c_protection_label": "thesis_break_watch_only", "trigger_outcome_label": "event_cap_4B_success_gene_therapy_regulatory_event_premium", "current_profile_verdict": "current_profile_4B_too_late_if_gene_therapy_regulatory_event_premium_not_capped", "calibration_usable": true, "forward_window_trading_days": 180, "calibration_block_reasons": [], "corporate_action_window_status": "clean_180D_window_after_2022_CA_and_post_suspension_tradable_history", "same_entry_group_id": "R7L92_C23_950160_2024-07-15_20300", "dedupe_for_aggregate": false, "aggregate_group_role": "4B_overlay_only", "is_new_independent_case": true, "reuse_reason": null, "independent_evidence_weight": 1.0, "do_not_count_as_new_case": false, "evidence_url_pending": true, "source_proxy_only": true}
```

### 25.4 score_simulation rows

```jsonl
{"row_type": "score_simulation", "profile_id": "e2r_2_1_stock_web_calibrated_proxy", "case_id": "R7L92_C23_ALTEOGEN_2024_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_POSITIVE", "trigger_id": "R7L92_C23_ALTEOGEN_2024_STAGE2_ACTIONABLE_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION", "symbol": "196170", "large_sector_id": "L7_BIO_HEALTHCARE_MEDICAL", "canonical_archetype_id": "C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION", "raw_component_scores_before": {"contract_score": 25, "backlog_visibility_score": 25, "margin_bridge_score": 25, "revision_score": 30, "relative_strength_score": 70, "customer_quality_score": 35, "policy_or_regulatory_score": 45, "valuation_repricing_score": 60, "execution_risk_score": 65, "legal_or_contract_risk_score": 35, "dilution_cb_risk_score": 0, "accounting_trust_risk_score": 5}, "weighted_score_before": 66, "stage_label_before": "Stage2-Watch", "raw_component_scores_after": {"contract_score": 60, "backlog_visibility_score": 55, "margin_bridge_score": 50, "revision_score": 55, "relative_strength_score": 75, "customer_quality_score": 65, "policy_or_regulatory_score": 55, "valuation_repricing_score": 55, "execution_risk_score": 35, "legal_or_contract_risk_score": 25, "dilution_cb_risk_score": 0, "accounting_trust_risk_score": 0}, "weighted_score_after": 78, "stage_label_after": "Stage2-Actionable", "changed_components": ["contract_score", "backlog_visibility_score", "margin_bridge_score", "revision_score", "policy_or_regulatory_score", "customer_quality_score", "execution_risk_score"], "component_delta_explanation": "platform_license_regulatory_commercialization_positive", "MFE_90D_pct": 124.09, "MAE_90D_pct": -9.3, "score_return_alignment_label": "platform_license_regulatory_commercialization_positive", "current_profile_verdict": "current_profile_kept_but_source_proxy_blocks_positive_delta"}
{"row_type": "score_simulation", "profile_id": "e2r_2_1_stock_web_calibrated_proxy", "case_id": "R7L92_C23_BORYUNG_2024_PHARMA_COMMERCIALIZATION_CHANNEL_FALSE_STAGE2", "trigger_id": "R7L92_C23_BORYUNG_2024_STAGE2_FALSE_POSITIVE_PHARMA_COMMERCIALIZATION_CHANNEL", "symbol": "003850", "large_sector_id": "L7_BIO_HEALTHCARE_MEDICAL", "canonical_archetype_id": "C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION", "raw_component_scores_before": {"contract_score": 25, "backlog_visibility_score": 25, "margin_bridge_score": 25, "revision_score": 30, "relative_strength_score": 70, "customer_quality_score": 35, "policy_or_regulatory_score": 45, "valuation_repricing_score": 60, "execution_risk_score": 65, "legal_or_contract_risk_score": 35, "dilution_cb_risk_score": 0, "accounting_trust_risk_score": 5}, "weighted_score_before": 66, "stage_label_before": "Stage2-Actionable", "raw_component_scores_after": {"contract_score": 5, "backlog_visibility_score": 10, "margin_bridge_score": 5, "revision_score": 10, "relative_strength_score": 25, "customer_quality_score": 10, "policy_or_regulatory_score": 25, "valuation_repricing_score": 25, "execution_risk_score": 90, "legal_or_contract_risk_score": 55, "dilution_cb_risk_score": 0, "accounting_trust_risk_score": 10}, "weighted_score_after": 53, "stage_label_after": "Stage1/Watch", "changed_components": ["contract_score", "backlog_visibility_score", "margin_bridge_score", "revision_score", "policy_or_regulatory_score", "customer_quality_score", "execution_risk_score"], "component_delta_explanation": "pharma_commercialization_channel_false_stage2", "MFE_90D_pct": 4.64, "MAE_90D_pct": -28.31, "score_return_alignment_label": "pharma_commercialization_channel_false_stage2", "current_profile_verdict": "current_profile_false_positive_if_pharma_commercialization_channel_counts_without_approval_reimbursement_revision_bridge"}
{"row_type": "score_simulation", "profile_id": "e2r_2_1_stock_web_calibrated_proxy", "case_id": "R7L92_C23_KOLONTISSUEGENE_2024_GENE_THERAPY_REGULATORY_EVENT_CAP_4B", "trigger_id": "R7L92_C23_KOLONTISSUEGENE_2024_STAGE4B_GENE_THERAPY_REGULATORY_EVENT_CAP", "symbol": "950160", "large_sector_id": "L7_BIO_HEALTHCARE_MEDICAL", "canonical_archetype_id": "C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION", "raw_component_scores_before": {"contract_score": 25, "backlog_visibility_score": 25, "margin_bridge_score": 25, "revision_score": 30, "relative_strength_score": 70, "customer_quality_score": 35, "policy_or_regulatory_score": 45, "valuation_repricing_score": 60, "execution_risk_score": 65, "legal_or_contract_risk_score": 35, "dilution_cb_risk_score": 0, "accounting_trust_risk_score": 5}, "weighted_score_before": 70, "stage_label_before": "Stage3-Yellow-like", "raw_component_scores_after": {"contract_score": 5, "backlog_visibility_score": 10, "margin_bridge_score": 5, "revision_score": 10, "relative_strength_score": 25, "customer_quality_score": 10, "policy_or_regulatory_score": 25, "valuation_repricing_score": 25, "execution_risk_score": 90, "legal_or_contract_risk_score": 55, "dilution_cb_risk_score": 0, "accounting_trust_risk_score": 10}, "weighted_score_after": 54, "stage_label_after": "Stage4B-watch", "changed_components": ["contract_score", "backlog_visibility_score", "margin_bridge_score", "revision_score", "policy_or_regulatory_score", "customer_quality_score", "execution_risk_score"], "component_delta_explanation": "gene_therapy_regulatory_event_cap_4B_guard", "MFE_90D_pct": 7.39, "MAE_90D_pct": -35.02, "score_return_alignment_label": "gene_therapy_regulatory_event_cap_4B_guard", "current_profile_verdict": "current_profile_4B_too_late_if_gene_therapy_regulatory_event_premium_not_capped"}
```

### 25.5 residual_contribution row

```jsonl
{"row_type": "residual_contribution", "round": "R7", "loop": "92", "large_sector_id": "L7_BIO_HEALTHCARE_MEDICAL", "canonical_archetype_id": "C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION", "fine_archetype_id": "BIO_PLATFORM_LICENSE_REGULATORY_COMMERCIALIZATION_BRIDGE_VS_PHARMA_CHANNEL_FALSE_STAGE2_AND_GENE_THERAPY_EVENT_CAP", "new_independent_case_count": 3, "reused_case_count": 0, "new_symbol_count": 2, "same_archetype_new_symbol_count": 2, "same_archetype_new_trigger_family_count": 3, "new_trigger_family_count": 3, "positive_case_count": 1, "counterexample_count": 2, "4B_case_count": 1, "4C_case_count": 0, "tested_existing_calibrated_axes": ["stage2_required_bridge", "local_4b_watch_guard", "full_4b_requires_non_price_evidence", "price_only_blowoff_blocks_positive_stage", "high_MAE_guardrail"], "residual_error_types_found": ["platform_license_regulatory_commercialization_positive", "pharma_commercialization_channel_false_stage2", "gene_therapy_regulatory_event_cap_4B"], "loop_contribution_label": "canonical_archetype_rule_candidate", "do_not_propose_new_weight_delta": true, "source_proxy_only_count": 3, "evidence_url_pending_count": 3}
```

### 25.6 narrative_only row

```jsonl
{"row_type":"narrative_only","case_id":"none","symbol":"none","large_sector_id":"L7_BIO_HEALTHCARE_MEDICAL","canonical_archetype_id":"C23_BIO_REGULATORY_APPROVAL_COMMERCIALIZATION","reason":"all selected rows have usable 180D stock-web windows; no narrative-only price row required","price_source":"Songdaiki/stock-web","usage":"not_weight_calibration"}
```

## 26. Deferred Coding Agent Handoff Prompt

### Purpose

You are now in the repository implementation phase. The attached Markdown files are v12 post-calibrated residual research outputs produced using the Songdaiki/stock-web OHLC atlas.

These MDs are not live candidate research. They are historical calibration research designed to extend the already-applied e2r_2_1_stock_web_calibrated profile.

Do not blindly apply every shadow row. Ingest the machine-readable rows and update the sector/canonical-archetype calibration ledger.

### Price source context

- Primary historical price source used by the research MD: Songdaiki/stock-web.
- Price basis: tradable_raw.
- Price adjustment status: raw_unadjusted_marcap.
- Price shard pattern: atlas/ohlcv_tradable_by_symbol_year/<prefix>/<ticker>/<year>.csv.
- Symbol profile pattern: atlas/symbol_profiles/<prefix>/<ticker>.json.

### Rules

- Use only calibration_usable=true rows for quantitative calibration.
- Do not count reused cases as new independent evidence unless independent_evidence_weight > 0.
- Soft-expansion rows should receive reduced evidence weight if the symbol already appears in the same archetype.
- Do not apply global deltas unless multiple large_sector_id values support the same direction.
- Positive score promotion requires non-price evidence and clean 180D MFE/MAE.
- 4B rows are overlay/risk calibration only.
- 4C rows are thesis-break/protection calibration only.
- False-positive rows should strengthen bridge requirements, not generate positive promotion.
- Production scoring must not change unless the user explicitly asks for another promotion batch.

### Expected repository tasks

1. Parse case / trigger / score_simulation / shadow_weight / residual_contribution rows.
2. Validate stock-web price source fields.
3. Validate large_sector_id and canonical_archetype_id.
4. Validate novelty and reuse fields.
5. Deduplicate same_entry_group_id and reused cases.
6. Aggregate by large_sector_id and canonical_archetype_id.
7. Update sector_shadow_profile and archetype_shadow_profile only.
8. Preserve global calibrated profile unless explicitly promoted.
9. Report new independent cases, counterexamples, and residual error types.
10. Add tests that bridge-missing C23 rows cannot promote positive stages.

### Expected output

- Concise implementation summary.
- Rows accepted/rejected.
- New sector/canonical archetype coverage.
- Existing axis strengthened/weakened/kept.
- No investment recommendation language.

## 27. Next Round State

```text
completed_round = R7
completed_loop = 92
next_round = R8
next_loop = 92
round_schedule_status = valid
round_sector_consistency = pass
```

## 28. Source Notes

- Main execution prompt: Songdaiki/stock_agent docs/core/e2r_v12_prompt_round_scheduler_corrected.txt.
- No-repeat index: Songdaiki/stock_agent docs/core/V12_Research_No_Repeat_Index.md.
- Price atlas: Songdaiki/stock-web atlas/manifest.json and per-symbol tradable shards.
- This file contains no investment recommendation and no production scoring change.
